All In Biotech

Drug Trial Radar · NCT05425940

Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer

A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer

Last checked: Nov 19, 2026Latest source record: Jul 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 901 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

901

Actual

Start

Sep 7, 2022

Primary completion

Jun 16, 2026

Study completion Jan 31, 2027

Sponsor

Lead sponsor
ExelixisIndustry
Sponsor type
Industry
First posted
Jun 21, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to evaluate XL092 + atezolizumab versus regorafenib in participants with microsatellite stable/microsatellite instability low (MSS/MSI-low) metastatic colorectal cancer (mCRC) who have progressed during, after or are intolerant to standard-of-care (SOC) therapy.

Conditions

  • Colorectal Cancer

Interventions

  • XL092Drug

    Supplied as tablets; administered orally daily.

  • AtezolizumabDrug

    Supplied as 1200 milligrams (mg)/20 milliliter (mL) vials; administered as a 1200 mg intravenous (IV) infusion once in a 3-week cycle (q3w).

  • RegorafenibDrug

    Supplied as 40 mg tablets; administered orally daily at 160 mg for the first 21 days of each 28-day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS) of XL092 + Atezolizumab Versus Regorafenib in All Randomized ParticipantsTime frame: Up to 32 months
  2. Overall Survival (OS) of XL092 + Atezolizumab Versus Regorafenib in Randomized Non-Liver Metastases (NLM) ParticipantsTime frame: Up to 32 months

Locations

133 sites in 16 countries. Site status is shown where the registry gives one.

  • Exelixis Clinical Site #65

    Jonesboro, Alabama

  • Exelixis Clinical Site #30

    Phoenix, Arizona

  • Exelixis Clinical Site #70

    Tucson, Arizona

  • Exelixis Clinical Site #9

    Duarte, California

  • Exelixis Clinical Site #55

    La Jolla, California

  • Exelixis Clinical Site #77

    Los Angeles, California

  • Exelixis Clinical Site #105

    Orange, California

  • Exelixis Clinical Site #80

    Santa Monica, California

  • Exelixis Clinical Site #5

    Santa Rosa, California

  • Exelixis Clinical Site #82

    Sylmar, California

  • Exelixis Clinical Site #58

    Torrance, California

  • Exelixis Clinical Site #81

    Whittier, California

  • Exelixis Clinical Site #125

    New Haven, Connecticut

  • Exelixis Clinical Site #16

    Miami Beach, Florida

  • Exelixis Clinical Site #60

    Orlando, Florida

  • Exelixis Clinical Site #4

    Marietta, Georgia

  • Exelixis Clinical Site #3

    Joliet, Illinois

  • Exelixis Clinical Site #102

    Indianapolis, Indiana

  • Exelixis Clinical Site #10

    Westwood, Kansas

  • Exelixis Clinical Site #47

    Lexington, Kentucky

  • Exelixis Clinical Site #7

    New Orleans, Louisiana

  • Exelixis Clinical Site #22

    St Louis, Missouri

  • Exelixis Clinical Site #8

    Billings, Montana

  • Exelixis Clinical Site #1

    Omaha, Nebraska

  • Exelixis Clinical Site #15

    Albuquerque, New Mexico

  • Exelixis Clinical Site #11

    New York, New York

  • Exelixis Clinical Site #59

    New York, New York

  • Exelixis Clinical Site #17

    The Bronx, New York

  • Exelixis Clinical Site #74

    Charlotte, North Carolina

  • Exelixis Clinical Site #6

    Cincinnati, Ohio

  • Exelixis Clinical Site #12

    Oklahoma City, Oklahoma

  • Exelixis Clinical Site #75

    Portland, Oregon

  • Exelixis Clinical Site #106

    Philadelphia, Pennsylvania

  • Exelixis Clinical Site #18

    Pittsburgh, Pennsylvania

  • Exelixis Clinical Site #103

    Pittsburgh, Pennsylvania

  • Exelixis Clinical Site #24

    Greenville, South Carolina

  • Exelixis Clinical Site #56

    Chattanooga, Tennessee

  • Exelixis Clinical Site #76

    Nashville, Tennessee

  • Exelixis Clinical Site #133

    Nashville, Tennessee

  • Exelixis Clinical Site #450

    Fairfax, Virginia

Showing 40 of 133 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.